Back to News
Market Impact: 0.32

From TASER to the Skies. Buy Axon Stock While It's Still Down 49%

Geopolitics & WarTechnology & InnovationInfrastructure & DefenseArtificial IntelligenceCompany FundamentalsAnalyst EstimatesProduct Launches
From TASER to the Skies. Buy Axon Stock While It's Still Down 49%

Axon is positioned to expand beyond TASERs and body cameras into the drone and counter-drone market, which it estimates at $20 billion. The article highlights Axon Air, its Skydio partnership, and the late-2024 Dedrone acquisition as catalysts, alongside AI revenue growth of over 700% in Q1 2026 and $14.3 billion in future bookings. Shares are down 49% from the August 2025 all-time high, but Wall Street still expects earnings growth of about 30% annually over the next three to five years.

Analysis

AXON is increasingly behaving less like a one-product public safety vendor and more like a vertically integrated security platform. That matters because the drone/counter-drone layer is not a stand-alone TAM story; it is a distribution wedge into existing agency budgets, where procurement friction is already paid down. The second-order winner is the software attach rate: once a department standardizes on one vendor for capture, storage, analytics, and airspace security, the marginal cost of adding more modules drops sharply and pricing power tends to increase over multiple budget cycles.

The more interesting implication is competitive, not geopolitical. A visible defense-use case accelerates buying intent for domestic perimeter security, stadiums, transit hubs, and municipal critical infrastructure, which should favor integrated vendors over point-solution drone firms. That likely pressures smaller counter-drone startups and hardware-only suppliers first; their products may get absorbed as components or lose on total cost of ownership. It also improves Axon's ability to leverage its installed base into multi-year contracts, which is typically where valuation expansion comes from, not from one-off product launches.

The key risk is timing mismatch: the headline can move in days, but procurement and certification are measured in quarters to years. If agencies decide drones are a tactical curiosity rather than a budget priority, the market may over-penalize the stock's near-term multiple while the revenue contribution remains deferred. There is also policy risk if federal rules around counter-drone authority tighten, which would slow monetization outside a few permitted end markets. At ~54x forward earnings, the stock is still priced for near-perfect execution, so any stumble in growth normalization could compress the multiple before the new category scales.